Related Experiment Video

Updated: Jul 16, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Activated PI3K signaling as an endogenous inducer of p53 in human cancer

Carolyn Lee1, Jung-Sik Kim, Todd Waldman

  • 1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, USA.

Cell Cycle (Georgetown, Tex.)
|March 3, 2007
PubMed

Insights

Activation of the phosphoinositide 3-kinase (PI3K) pathway, through PTEN loss or PIK3CA mutations, triggers p53 signaling. This suggests p53 activation acts as a failsafe, potentially driving p53 mutations in cancer.

Area of Science:

  • Cellular biology
  • Molecular oncology
  • Cancer genetics

Background:

  • Mammalian cells possess complex pathways regulating oncogenes and tumor suppressor genes.
  • Understanding these pathways is crucial for developing cancer therapies.
  • The phosphoinositide 3-kinase (PI3K) pathway plays a critical role in cell growth and survival.

Purpose of the Study:

  • To investigate the functional consequences of PI3K pathway dysregulation on p53 signaling.
  • To determine if loss of PTEN or activating PIK3CA mutations impact p53 activity.
  • To explore the relationship between PI3K pathway activation and p53 mutation in tumorigenesis.

Main Methods:

  • Analysis of human cell lines with specific genetic alterations.
  • Assessment of phosphoinositide 3-kinase (PI3K) signaling pathway activation.
  • Evaluation of p53 signaling pathway functional activation.
  • Investigation of PTEN and PIK3CA mutation status.

Main Results:

  • Inactivating PTEN mutations or activating PIK3CA mutations lead to functional activation of p53 signaling.
  • p53 activation appears to be a response to PTEN loss or PI3K oncogenic activation.
  • These events create selective pressure that may lead to p53 mutations.

Conclusions:

  • Dysregulation of the PI3K pathway, via PTEN or PIK3CA, activates p53 as a cellular safeguard.
  • The interplay between PI3K pathway mutations and p53 activation is a key factor in cancer development.
  • Targeting these pathways could offer novel therapeutic strategies for cancer.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...